Thanks Association for Diagnostics & Laboratory Medicine for shortlisting us for Disruptive Tech Award. Actiphage TB, first test to confirm TB disease progression by detecting live bacteria in the blood. Will enable targeting of treatment to those at most risk, an unmet need for #EndTB campaign
bit.ly/3UxQjvo

Phage therapy can be the last resort for some patients. We shared our experiences of selecting, purifying and transporting phage with Phage Directory a community of hero researchers and clinicians who are matching phages with bacterial infections. bit.ly/3Qhm0qj

Well done team. 'Gaining ISO 13485 accreditation has required a huge effort and I am so proud of what has been achieved.' says CEO Jane Theaker. 'It provides assurance that our Actiphage TB Blood test is being developed to the highest standards'
bit.ly/3xgsMpk

World TB Day 2024 is a moment to take stock of developments in the fight to end tuberculosis; a treatable, preventable disease that is still the commonest cause of death from an infectious disease. New diagnostics are key
#WorldTBDay2024 #YesWeCanEndTB pbdbio.com/world-tb-day-2…

Interesting study by LSTM shows sensitivity needed when screening household contacts for incipient TB. Highlights the need also for improved non-invasive diagnostics #WorldTBDay24 #YesWeCanEndTB

Drug-resistant TB accounts for 1 in 3 deaths from AMR so fitting theme for 5th Annual Infectious Disease and Molecular Diagnostics Conference ahead of #WorldTBDay Helen Dent British In Vitro Diagnostics Association (BIVDA) discussing new advances including Actiphage. #WeCanEndTB bit.ly/3IMGpPH

80 percent of people with TB do not have a persistent cough and yet are still infective. Research Amsterdam UMC The Lancet Infectious Diseases ahead of #worldtbday2024 highlights urgent need for biomarkers for disease progression to break the cycle of infection #EndTB bit.ly/3VnwKXp

Are phage-based diagnostics the next big thing in the fight against tuberculosis? Article in The Pathologist by Dr Pranab Haldar Leicester's Research discusses findings of research using Actiphage TB and progress towards World Health Organization (WHO) target product profile #EndTB
bit.ly/3uJmjma

Is ending TB (finally) within sight? New report from TB Alliance & FIND concludes progress in new tool dev is accelerating. Actiphage aligns with their goals, offering potential for a simpler way to screen individuals at high risk of disease progression
bit.ly/3SIiZ2x

Delighted to be finalists for #BioNowAwards Social Impact Award for our work to #EndTB . Proud to be alongside: leading cancer centre The Christie NHS, Health Equity North fighting health inequalities and the Afro-Caribbean Commercial Science Network Afro-Caribbean Commercial Science Network Thanks sponsors Square One Law

Drug-resistant Tuberculosis accounts for 1 in 3 deaths from antimicrobial resistance (AMR)*, meaning grim predictions for a ‘post-antibiotic age’ are already a reality for many. Looking forward to hearing about solutions #BioInfect @bionow iiCON: Infection Innovation Consortium Science and Technology Facilities Council

Thank you TB_NewsDaily for sharing. Actiphage is a breakthrough diagnostic that offers hope for better targeted intervention to prevent disease and limit onward transmission, key components of WHO’s #EndTb strategy.

A groundbreaking study for phage-diagnostics, please share CentreforPhageResearch Dr. Sabrina Green, PhD Phage Directory Together we can #EndTB

Study The Lancet Microbe reveals a potential novel biomarker of TB risk in household contacts. It shows significant association between Mtb DNA detected by Actiphage in the blood and progressive tuberculosis infection Leicester's Research Ben Swift #EndTB bit.ly/3OfhdV1

Antimicrobial resistance has been declared by the World Health Organization (WHO) as one of the top 10 global public health threats. Ben Swift@BMCS88 Ben Swift, a pioneer in phage-based diagnostics, is to present in the 'What's in the Pipeline' session at #BioInfect 2024. Bionow
bit.ly/3RHoLCm

#FullHouse & great energy at World Health Organization (WHO)'s Global #EndTB Symposium today with a spotlight on taking forward committments made by world leaders at the #UN High Level Meeting on TB & translating this rapidly to action over next 5 years. Distinguished line-up of speakers #UnionConf2023 🧵

Enjoyed pitching Aciphage our phage-based diagnostic for #Tuberculosis LSX Leaders #Investival Showcase. Thank you Jefferies for hosting and giving us this opportunity. Great to see you Hannah Mercia Asset Management PLC #EndTB

Delighted that Professor Cath Rees' work developing phage-based diagnostics for human TB and bovine TB has been recognised with this prestigious Microbiology Society award. Well done to all the award winners. #EndTB #Microbio24

First test kit for Actiphage dispatched for assessment R2D2 TB Network Adithya Cattamanchi, PI says “Improved diagnostics for TB are urgently required, so we are pleased to be evaluating a novel diagnostic in a community where it is most needed.” bit.ly/40ePYij

Great line-up in the jury for the 42Plus1 grand finale pitch at DxPxEU - chaired by Laura Richter McKinsey & Company. Looking forward to presenting our phage-based diagnostics for early detection of active #tuberculosis ; one of the world's most deadly diseases #YesWeCanEndTB